In a paper published in MedComm – Future Medicine, a Chinese research team presents ImmunoCheckDB, a comprehensive web platform integrating meta-analysis and multiomic data to discover cancer immunotherapy biomarkers. The platform curates 173 studies on immune checkpoint inhibitor (ICI) therapies, covering survival outcomes for 93,234 individuals across 18 cancer types and 30 ICI regimens, enabling pan-cancer exploration of molecular markers for ICI efficacy.

- Development of "dynamic nanomedicines" for efficient delivery of nucleic acid medicines to sentinel lymph nodes.

- Delivering nucleic acid medicines to sentinel lymph nodes, which serve as a checkpoint for cancer metastasis, activates the immune system, helping to suppress cancer metastasis and recurrence.

- Enhancing cancer immunotherapy to make it effective against immunotherapy-resistant tumors.

- Precise size adjustment of nanomedicines (approximately 10 nm) enables delivery to sentinel lymph nodes.

- Precision nanomedicine design via advanced computational modelling.

- Aim to start clinical trials within five years.

- This announcement is part of a research project conducted by Professor Kanjiro Miyata of the Graduate School of Engineering, The University of Tokyo (Visiting Research Scientist at iCONM), in collaboration with iCONM researchers.